CUPERTINO, Calif., March 4, 2019 /PRNewswire/ -- In conjunction
with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2018
financial results press release, you are invited to listen to a
conference call that will be broadcast live over the internet on
Thursday, March 7, 2019 at
4:30 pm Eastern Time (1:30 pm Pacific Time).
A live audio webcast of the presentation will be available by
accessing DURECT's homepage at www.durect.com and clicking
"Investor Relations." If you are unable to participate during
the live webcast, the call will be archived on DURECT's website
under Audio Archive in the "Investor Relations" section.
About DURECT Corporation
DURECT is a biopharmaceutical company actively developing
therapeutics based on its Epigenetic Regulator Program and
proprietary drug delivery platforms. DUR‑928, a new chemical
entity in Phase 2 development, is the lead candidate in DURECT's
Epigenetic Regulator Program. An endogenous, orally
bioavailable small molecule, DUR-928 has been shown in preclinical
studies to play an important regulatory role in lipid homeostasis,
inflammation, and cell survival. Human applications may include
acute organ injury such as Alcoholic Hepatitis (AH), hepatic and
renal diseases such as nonalcoholic steatohepatitis (NASH) and
Primary Sclerosing Cholangitis (PSC), and inflammatory skin
conditions such as psoriasis and atopic dermatitis. DURECT's
advanced oral and injectable delivery technologies are designed to
enable new indications and enhanced attributes for small-molecule
and biologic drugs. Late stage product candidates in this
category include POSIMIR® (Extended Release
Bupivacaine), an investigational locally-acting, non-opioid
analgesic intended to provide up to 3 days of continuous pain
relief after surgery, and ORADUR®-Methylphenidate ER
Capsules, approved in Taiwan as
Methydur Sustained Release Capsules, where it is indicated for the
treatment of attention deficit hyperactivity disorder (ADHD). In
addition, for the assignment of certain patent rights, DURECT
receives single digit sales-based earn-out payments from U.S. net
sales of Indivior's PERSERIS™ (risperidone) drug for
schizophrenia, which was approved in July 2018. For more
information, please visit www.durect.com.
NOTE: ORADUR®, POSIMIR® and
SABER® are trademarks of DURECT Corporation.
Other referenced trademarks belong to their respective owners.
DUR-928 and POSIMIR are drug candidates under development and have
not been approved for commercialization by the U.S. Food and Drug
Administration or other health authorities.
DURECT Forward-Looking Statement
The statements in
this press release regarding the potential benefits and uses of
DURECT's drug candidates, including the potential use of DUR-928 to
treat Alcoholic Hepatitis, hepatic and renal diseases such as
nonalcoholic steatohepatitis (NASH) and Primary Sclerosing
Cholangitis (PSC), and inflammatory skin conditions such as
psoriasis and atopic dermatitis, the potential use of POSIMIR to
treat post-surgical pain, the potential use of
ORADUR-Methylphenidate to treat ADHD, and the potential for
sales-based earn-out payments from the sale of Indivior's PERSERIS
to treat schizophrenia are forward-looking statements involving
risks and uncertainties that can cause actual results to differ
materially from those in such forward-looking statements. Potential
risks and uncertainties include, but are not limited to, the
possibility that studies of DUR-928 will not replicate results from
earlier preclinical or clinical trials, the risks that PERSERIS
will not obtain market acceptance and meaningful sales, as well as
possible adverse events associated with the use of PERSERIS,
POSIMIR, ORADUR-Methylphenidate and DUR-928, and delays and costs
due to additional work or other requirements imposed by regulatory
agencies for continued development, approval or sale of POSIMIR,
ORADUR-Methylphenidate and DUR-928. Further information
regarding risks related to DUR-928, POSIMIR and
ORADUR-Methylphenidate and other risks related to DURECT is
included in DURECT's Form 10-Q filed on November 8, 2018 under the heading "Risk
Factors."
View original
content:http://www.prnewswire.com/news-releases/durect-corporation-invites-you-to-join-its-fourth-quarter-2018-earnings-conference-call-300805393.html
SOURCE DURECT Corporation